Tempus AI, Inc. (NASDAQ:TEM – Get Free Report) COO Ryan Fukushima sold 2,868 shares of the company’s stock in a transaction on Wednesday, February 19th. The shares were sold at an average price of $81.87, for a total value of $234,803.16. Following the transaction, the chief operating officer now directly owns 944,460 shares in the company, valued at $77,322,940.20. This trade represents a 0.30 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Ryan Fukushima also recently made the following trade(s):
- On Tuesday, February 4th, Ryan Fukushima sold 20,000 shares of Tempus AI stock. The shares were sold at an average price of $62.50, for a total value of $1,250,000.00.
- On Tuesday, January 7th, Ryan Fukushima sold 20,000 shares of Tempus AI stock. The shares were sold at an average price of $39.61, for a total value of $792,200.00.
- On Monday, December 16th, Ryan Fukushima sold 3,500 shares of Tempus AI stock. The shares were sold at an average price of $40.23, for a total value of $140,805.00.
- On Wednesday, December 11th, Ryan Fukushima sold 120,000 shares of Tempus AI stock. The stock was sold at an average price of $42.51, for a total value of $5,101,200.00.
Tempus AI Price Performance
TEM opened at $68.09 on Friday. Tempus AI, Inc. has a 12-month low of $22.89 and a 12-month high of $91.45. The business has a 50 day moving average of $50.29 and a 200-day moving average of $51.72. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 8.17.
Institutional Trading of Tempus AI
Analyst Upgrades and Downgrades
Several brokerages have issued reports on TEM. Loop Capital lowered their price target on Tempus AI from $57.00 to $52.00 and set a “buy” rating for the company in a report on Tuesday, January 14th. Guggenheim initiated coverage on Tempus AI in a report on Monday, December 9th. They set a “buy” rating and a $74.00 price objective for the company. Bank of America increased their price objective on Tempus AI from $52.00 to $54.00 and gave the stock a “neutral” rating in a report on Friday, December 13th. Needham & Company LLC reiterated a “buy” rating and set a $56.00 price objective on shares of Tempus AI in a report on Tuesday, January 14th. Finally, TD Cowen restated a “buy” rating and issued a $74.00 price target (up from $58.00) on shares of Tempus AI in a research note on Wednesday, February 5th. Four analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $58.55.
Read Our Latest Stock Analysis on TEM
Tempus AI Company Profile
Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.
Recommended Stories
- Five stocks we like better than Tempus AI
- Stock Sentiment Analysis: How it Works
- Unity Stock: Is a True Turnaround Finally Taking Shape?
- The Risks of Owning Bonds
- DuPont’s Electronics Spinoff: The Start of Something Big
- Bank Stocks – Best Bank Stocks to Invest In
- The Trade Desk Crashes on Earnings, But Growth Catalysts Persist
Receive News & Ratings for Tempus AI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tempus AI and related companies with MarketBeat.com's FREE daily email newsletter.